Hematology and Oncology, University Medicine Göttingen, Göttingen, and Hematology and Oncology, Pius Hospital Oldenburg, Oldenburg, Germany.
Dermatology. 2012;225(2):179-82. doi: 10.1159/000342786. Epub 2012 Oct 20.
Erlotinib inhibits the tyrosine kinase of epidermal growth factor receptor (EGFR) and is successfully used in lung cancer treatment. EGFR is essential in skin development and function and may have a role in the pathogenesis of psoriasis. Cutaneous side effects are very common in patients treated with erlotinib, and therapeutic use of erlotinib in dermatological disorders has therefore not been considered. We report two cases of patients with lung cancer and concomitant psoriasis treated with erlotinib with complete resolution of the skin problems. We present a review of the current literature on the topic.
厄洛替尼抑制表皮生长因子受体（EGFR）的酪氨酸激酶，成功用于肺癌治疗。EGFR 在皮肤发育和功能中必不可少，可能在银屑病的发病机制中起作用。接受厄洛替尼治疗的患者常出现皮肤副作用，因此未考虑将厄洛替尼用于皮肤病治疗。我们报告两例肺癌合并银屑病患者，接受厄洛替尼治疗后皮肤问题完全缓解。我们对该主题的现有文献进行了回顾。
